RadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 25.0%, EPS fell 47.4%, free cash flow fell 43.2% and total debt rose 21.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow RDNT
RadNet, Inc. (RDNT) EV/Sales
As of 16 October 2026, RadNet, Inc. (RDNT) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from 0.9× (March 2020) to 3.8× (November 2024); the current reading is higher than 87% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.8× | (5.14%) |
| FY2024 | 2.9× | 73.28% |
| FY2023 | 1.7× | 32.48% |
| FY2022 | 1.3× | (25.72%) |
| FY2021 | 1.7× | 14.34% |
| FY2020 | 1.5× | 0.67% |
| FY2019 | 1.5× | 31.31% |
| FY2018 | 1.1× | 5.70% |
| FY2017 | 1.1× | 6.96% |
| FY2016 | 1.0× | (6.84%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.4× | 3.35% |
| Mar 2026 | 2.3× | (17.35%) |
| Dec 2025 | 2.8× | (9.68%) |
| Sep 2025 | 3.1× | 30.85% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RDNT RadNet, Inc. | 2.6× |
| QGEN QIAGEN N.V. compare | 4.9× |
| VCYT Veracyte, Inc. compare | 5.3× |
| SHC Sotera Health Company compare | 5.7× |
| CDNA CareDx, Inc. compare | 6.4× |
| BLLN BillionToOne, Inc. compare | 10.3× |
| ADPT Adaptive Biotechnologies Corporation compare | 12.4× |
| TWST Twist Bioscience Corporation compare | 18.8× |
| GRAL GRAIL, Inc. compare | 25.5× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)